- Home
- KEY vs BNTX Comparison
KEY vs BNTX Comparison
Compare KEY & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | BNTX |
|---|---|---|
| Founded | 1825 | 2008 |
| Country | United States | Germany |
| Employees | 17883 | 6772 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 25.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KEY | BNTX |
|---|---|---|
| Price | $19.88 | $101.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $22.68 | ★ $140.31 |
| AVG Volume (30 Days) | ★ 15.1M | 541.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.33 | $2.54 |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.73 | $90.12 |
| 52 Week High | $23.35 | $124.00 |
Technical Indicators
Market Signals| Indicator | KEY | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 38.85 |
| Support Level | $17.07 | $99.63 |
| Resistance Level | $21.69 | $113.12 |
| Average True Range (ATR) | 0.68 | 3.16 |
| MACD | -0.22 | -1.10 |
| Stochastic Oscillator | 16.00 | 24.84 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 15 states, but it is predominantly concentrated in its three largest markets: Ohio, New York, and Washington. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.